🔗 Share this article

As America continues making sweeping adjustments to its vaccination recommendations, one figure appears in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations during the global health crisis and has zeroed in on potential fatalities following Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Program

Public health authorities had intended to announce radical revisions to the pediatric immunization program in December, synchronizing the US with the Danish vaccine program, according to reports – a major change that would put the US out of alignment with a large portion of the international standard with insufficient data for improved outcomes. This reveal has been postponed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to speak at the event. She was newly appointed interim head of the FDA’s CDER, the fifth person to lead the center this calendar year.

A Shift at the Agency

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon rolling back previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting some pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a society with universal health coverage and a citizenry approximately the size of Wisconsin’s.

So far comments, she has kept her attention on vaccination policy – traditionally the responsibility of Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or management, which has been typical for previous directors of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a major agency. She is not an expert in drug approvals.”

Previous heads of the center would “grasp laws and regulations and the underlying principles of drug development”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that prior appointees who ran CBER have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner pointed out.

“The public just focuses on the innovative therapies, but the generic drug division approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and other areas, and each of these need to be looked after,” Woodcock explained. “The thing you neglect, that is the part that I always told people is going to bite you.”

Additionally, a significant management component to the role, which supervises over 5,000 employees. “It is a enormous leadership role, if you execute it properly,” the former official added.

Agency Reaction and Controversial Programs

Regarding inquiries about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson stated that the “inquiries stem from inaccurate assumptions”.

“Her experience is consistent with the responsibilities of her job,” the spokesperson said, citing the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a controversial rapid medication authorization process that apparently worried her predecessors. “How are these drugs being picked for this fast-track system? Who makes the calls?” Dr. Howard asked. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he remarked, “the FDA seems to be moving towards laxer oversight of most medications, except for shots.”

Established Track Record on Immunizations

With immunizations, Høeg has a more established, if problematic, past, some experts have noted. She published a research paper using unverified volunteer-provided data to determine the frequency of myocarditis after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming federal leadership included altering rules for recently developed shots and discontinuing “non-essential” immunizations, she stated following the vote on a podcast. At the agency, Høeg has allegedly floated the idea of barring adolescent males from receiving Covid vaccines.

“She is an complete true believer who commences with her preconceived notions and tailors the evidence to accommodate the science in a extremely deceptive, untruthful way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|